The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
In the brand-new tardive dyskinesia market, doctors initially preferred Neurocrine’s Ingrezza over Teva’s Austedo. But that edge is weakening, one analyst says. These days, doctors are viewing the two ...
Additional data to be presented examining the safety and tolerability of AUSTEDO during periods of titration and maintenance “Tardive dyskinesia causes involuntarily, uncontrollable movements, that ...
Downtrodden Teva Wednesday got some good news—and Neurocrine got some company. The FDA approved the Israeli drugmaker’s Austedo to treat movement disorder tardive dyskinesia (TD) in adults, marking ...
PARSIPPANY, N.J., and TEL AVIV, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the ...
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 12 presentations across its ...
New analysis from the IMPACT-TD Registry demonstrates that treatment with AUSTEDO and AUSTEDO XR led to reductions in Abnormal Involuntary Movement Scale (AIMS) scores in all participants, which were ...
While Part A of the IMPACT-TD Registry demonstrated the broad impact TD has on individuals beyond physical movements, these initial findings from Part B reflect patient-reported improvements in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results